Victoria, British Columbia, Canada, April 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins. The immediate benefits to ImmunoPrecise is that B-cell services will now be provided in-house and it greatly increases the profit margin of the services offered by IPA.
The addition of B-cell capabilities establishes ImmunoPrecise as the first full-service discover antibody CRO in North America or Europe to provide a globally-operating, full pipeline of therapeutic discovery offerings from target selection, on-site animal access, advanced hybridoma discovery, B-cell screening and sequencing, antibody characterization, phage display, in vitro and in vivo analyses.
ImmunoPrecise’s new facility uses innovative technology that allows for antibody screening from any species of animals, allowing for a greater diversity of animal repertoires, from any tissue sample, to allow for faster, deeper antibody screening compared to traditional technologies.
Our new facility’s technology greatly increases the speed of antibody discovery platforms and maintains native antibody pairing, recently demonstrated to be superior to by decreasing false positives, and providing antibodies of higher sensitivity and specificity.
IPA’s technology is applicable to any protein class, including complex therapeutic targets such as GPCRs and ion channels.
With the launch of our new facility, IPA is able to guarantee the outcomes of producing target specific antibodies for each campaign.
The addition of the B-cell sorting facility completes IPA’s full service platform for antibody discovery process of antibodies, and is expected to be followed with the opening of a similar facility in Europe the second half of 2018.
“The opening of our new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins completes our full service antibody discovery platform to achieve the value chain for the discovery of therapeutic antibodies ,” said Jennifer L. Bath, President and CEO, at IPA. “B-cell screening, sorting and sequencing capability provides enhanced technological capacity that substantially increases throughput and identification therapeutically relevant antibodies.”
Since 2009, IPA has provided clients access to single B-cell sorting capability however with the increased capability and technology of the new facility, IPA will combine its B-cell sorting capability with sequencing and screening technology to ensure it can bring all these capabilities to its antibody discovery platform.
“The industry has increasingly identified its needs to out-source its antibody discovery process to a single source provider who has the technical and technological capability for high throughput and higher probability of identifying therapeutically relevant antibodies,” said Jennifer L. Bath, President and CEO of IPA. “We anticipate IPA’s global footprint and antibody discovery industry leadership will enable the further growth and expansion of our platform.”
The whole value chain of the IPA antibody discovery platform provides a single source for antibody discovery of therapeutic antibodies from inception of the target to clinical trials.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care and in association with U-Protein Express B.V. its subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands.
The services offered to customers include the development of wild-type and humanized mouse and rat monoclonal antibodies and recombinant rabbit monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically-based assays, recombinant protein manufacturing, and advanced solutions to challenges faced by clients in antibody-related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
ImmunoPrecise employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO
3204-4464 Markham Street.
Victoria, BC V8Z 7X8
For investor relations please contact:
Email: [email protected]
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.